Fulcrum Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
a)
None.
b)
Director and Officer Trading Plans and Arrangements.
On December 26, 2024, Alex C. Sapir, our President and Chief Executive Officer, adopted a trading plan for the potential sale of up to 360,000 shares of our common stock and for the potential exercise of vested stock options and the associated sale of up to 360,000 shares of our common stock. The trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and was expected to remain in effect until December 31, 2025. On January 16, 2025, Mr. Sapir modified such 10b5-1(c) plan, which extended the date from which sales may commence and the price at which sales may be made, as well as the expiration date, which is now May 15, 2026, as so amended.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.